CA2501756C - Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage - Google Patents

Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage Download PDF

Info

Publication number
CA2501756C
CA2501756C CA2501756A CA2501756A CA2501756C CA 2501756 C CA2501756 C CA 2501756C CA 2501756 A CA2501756 A CA 2501756A CA 2501756 A CA2501756 A CA 2501756A CA 2501756 C CA2501756 C CA 2501756C
Authority
CA
Canada
Prior art keywords
lys
glu
leu
arg
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2501756A
Other languages
English (en)
French (fr)
Other versions
CA2501756A1 (en
Inventor
Jennifer E. Van Eyk
Jeremy A. C. Simpson
Ninetta Buscemi
Michelle K. Quick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Publication of CA2501756A1 publication Critical patent/CA2501756A1/en
Application granted granted Critical
Publication of CA2501756C publication Critical patent/CA2501756C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
CA2501756A 2002-10-11 2003-10-10 Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage Expired - Fee Related CA2501756C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/270,838 2002-10-11
US10/270,838 US7196169B2 (en) 2002-10-11 2002-10-11 Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
PCT/CA2003/001523 WO2004034060A2 (en) 2002-10-11 2003-10-10 Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage

Publications (2)

Publication Number Publication Date
CA2501756A1 CA2501756A1 (en) 2004-04-22
CA2501756C true CA2501756C (en) 2013-01-29

Family

ID=32069017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2501756A Expired - Fee Related CA2501756C (en) 2002-10-11 2003-10-10 Isolated post-translationally modified proteins for monitoring and diagnosing muscle damage

Country Status (6)

Country Link
US (1) US7196169B2 (enExample)
EP (1) EP1554587A2 (enExample)
JP (1) JP2006502203A (enExample)
AU (1) AU2003273674A1 (enExample)
CA (1) CA2501756C (enExample)
WO (1) WO2004034060A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618782B1 (en) 1999-10-18 2009-11-17 Queen's University At Kingston Methods of diagnosing muscle damage
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
CA2419295A1 (en) * 2000-08-21 2002-02-28 Queen's University At Kingston Methods and kits for separation and detection of proteins in biological samples
ATE520981T1 (de) 2002-10-02 2011-09-15 Dmi Biosciences Inc Diagnose und überwachung von krankheiten
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
CA2667012A1 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
CN1974594B (zh) * 2006-11-16 2010-04-14 中国人民解放军军事医学科学院卫生学环境医学研究所 人心肌肌钙蛋白ⅰ亚基核酸适配子及应用
JP5376370B2 (ja) 2007-06-20 2013-12-25 日本電気株式会社 肝細胞がんタンパク質マーカーとそれを用いた肝細胞がんの検出方法
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
EP3178846B1 (en) * 2010-02-17 2018-08-22 Cedars-Sinai Medical Center Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2013085367A1 (en) * 2011-12-09 2013-06-13 Kyungpook National University Industry-Academic Cooperation Foundation Cardiac troponin i-targeting peptide and use thereof
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN111662909B (zh) * 2019-03-05 2022-07-15 中国科学技术大学 心肌肌钙蛋白i特异性核酸适配体及其应用
BR102021020613A2 (pt) * 2021-10-14 2023-04-18 Universidade Federal Do Rio De Janeiro Método de investigação proteômica em amostra para diagnóstico da rabdomiólise e kits para realização do mesmo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027156A1 (en) 1993-05-17 1994-11-24 Fortron Bioscience, Inc. Assay for cardiac troponin i
US5702905A (en) 1994-09-28 1997-12-30 Spectral Diagnostics Monoclonal antibody to human ventricular myosin light chains
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
US6227658B1 (en) 1997-06-23 2001-05-08 Kabushiki Kaisha Toshiba Apparatus and method for forming thin film using ink-jet mechanism
US7384751B1 (en) 1997-07-16 2008-06-10 Queen's University At Kingston Methods of diagnosing muscle damage
US6248546B1 (en) * 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex

Also Published As

Publication number Publication date
WO2004034060A2 (en) 2004-04-22
JP2006502203A (ja) 2006-01-19
US20040072255A1 (en) 2004-04-15
US7196169B2 (en) 2007-03-27
CA2501756A1 (en) 2004-04-22
AU2003273674A1 (en) 2004-05-04
EP1554587A2 (en) 2005-07-20
WO2004034060A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
US7196169B2 (en) Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
Bodor et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue
US8481274B2 (en) Methods and kits for separation and detection of proteins in biological samples
US20120052592A9 (en) Method for determining prognosis of acute central nervous system disorder
JP7492711B2 (ja) アルツハイマー病バイオマーカー
CA2492980A1 (en) Protein for diagnosing diabetic retinopathy
CN113287013B (zh) 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
US8420331B2 (en) Type IV collagen-like immunoreactive peptide
US20100129851A1 (en) Methods of diagnosing muscle damage
AU2001287423A1 (en) Methods and kits for separation and detection of proteins in biological samples
US20250044290A1 (en) Biomarkers For Detecting Human Glycogen Phosphorylase Isoenzyme BB
KR100689995B1 (ko) 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법
CA2243372C (en) Methods of diagnosing muscle damage
JP5120843B2 (ja) 自己免疫性膵炎の検査方法及び検査試薬
Panteghini et al. Rapid and specific immunoassay for cardiac troponin I in the diagnosis of myocardial damage
JP5413863B2 (ja) 劇症１型糖尿病の検査方法及び検査試薬
US20130115633A1 (en) Methods & Devices for Diagnosing Cardiac Disorders
US20060269963A1 (en) Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it
JPH0424554A (ja) カルパスタチン異常症の検出方法及びキット
JP2021021715A (ja) 骨質の評価方法
HK1166368A1 (zh) 使用一组新型低丰度人类血浆蛋白生物标记对肝纤维化进行临床诊断

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151013